Mint Quick Edit | Johnson & Johnson’s $5.5 billion offer to settle cancer-risk suits: is money enough?
This American pharma major wants to end its nightmare of lawsuits over allegations of ovarian cancer-causing talcum powder. But its therapeutic advances—in oncology, especially—might determine whether it can rescue J&J as a brand.
Post Comment